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Edited by Francesc PosasAbstract Although vascular smooth muscle cells (VSMCs) are
widely used in cardiovascular research, their phenotypic change
under various culture conditions is problematic to evaluate the
experimental results obtained. The levels of angiotensin (Ang)
type 1/2 (AT1/AT2) receptors as well as contractile and struc-
tural proteins are degraded through culture passages. The pres-
ent study demonstrated that heparin recovered Ang receptors
and diﬀerentiation markers, such as desmin, SM-22 and smooth
muscle a-actin in VSMCs at the ninth passage. Heparin also
potenciated Ang II-induced activation for ERK1/2 and p38.
These results suggest a potential value of heparin-treated
VSMCs as the model for analysis of Ang-mediated signal trans-
duction under physiological condition.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Primary culture of vascular smooth muscle cells (VSMCs)
have been widely used in the research ﬁeld of vascular biology
and cardiovasucular medicine. The cells derived from aortic/
arterial tunica media express native proteins including smooth
muscle a-actin, smooth muscle myosin heavy chains, smooth
muscle myosin light chains, smooth muscle a-tropomyosin,
SM-22, desmin, calponin, h-caldesmon, vinculin, metavinculin
and telokin, which are indices for contractile phenotype of
VSMCs [1]. Morphologic and functional proﬁles such as a
spindle-like shape and agonist-elicited contracted responses
also provide evidence for physiological nature of the cells.
However, VSMCs multiplying in a medium containing fetal
bovine serum (FBS) rapidly lose their contractile features*Corresponding author. Fax: +81 45 701 3738.
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doi:10.1016/j.febslet.2004.11.093and become ‘‘synthetic’’ cells with decrease in diﬀerentiation
markers [2–4].
Angiotensin (Ang) type 1 (AT1) receptor plays a major
role in regulating hemodynamics and architecture of cardio-
vascular system. Cultured VSMCs are known to express
abundant AT1 receptors and show activation of intracellular
signaling pathways in response to Ang II. While VSMCs in a
conﬂuent state actually reproduce AT1 receptor-mediated cell
functions, the cells in a proliferating state do not [5].
Through several culture passages, they rapidly lose ability
to respond normally to Ang II with a decrease in AT1 recep-
tor expression [6].
Various substances including endogenous growth factors
and media supplements aﬀect the phenotypes of cultured cells.
In VSMCs, heparin [7,8], transforming growth factor (TGF)-
b1, TGF-b2 [9,10] and all-trans-retinoic acid (tRA) [11] are
known to promote cell diﬀerentiation. Among them, heparin
has the most potent eﬀect in terms of inhibition of prolifera-
tion and migration, and of upregulation of diﬀerentiation
markers [12]. For the present time, there is no description con-
cerning the eﬀect of heparin on AT1 receptor expression and
its intracellular signal transduction in cultured VSMCs.
The present study examined the eﬀects of heparin on AT1
receptor expression and intracellular signal responses to Ang
II in VSMCs; the aim was to investigate the utility of hepa-
rin-treated VSMCs as a model maintaining a contractile phe-
notype. Cellular responses to Ang II were assessed by
activation of ERK1/2 and p38. We also describe mRNA
expression of Ang type 2 (AT2) receptor during heparin-
treatment.2. Materials and methods
2.1. Cell culture
VSMCs from the thoracic aorta of 4-week-old male Wister rats were
prepared by the explant method and cultured in Dulbeccos modiﬁed
Eagles medium (D-MEM) containing 10% FBS at 37 C in a humid-
iﬁed atmosphere of 95% air and 5% CO2 as described previously [13].
The cells were studied from the third to the ninth passage. Subconﬂu-
ent VSMCs were incubated in D-MEM containing 1% FBS with or
without 200 mg/mL heparin (Sigma, MO, USA). Medium was changed
after 3 days and cells were treated for 6 days. When VSMCs were trea-
ted for 4 days or less, the eﬀects were not signiﬁcantly observed. Cel-
lular viability was checked by CytoTox96 (Promega, WI, USA).blished by Elsevier B.V. All rights reserved.
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Fig. 1. AT1 and AT2 receptor mRNA expression in VSMCs. VSMCs
were passaged with trypsin from the third (P-3) to the ninth (P-9)
passage. Subconﬂuent VSMCs were incubated in D-MEM containing
1% FBS for 6 days. Expressions of the P-3 group were set at 1.0 (n = 3
each). Results are expressed as means ± S.E.M. \P < 0.05 vs. P-3.
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Fig. 2. AT1 receptor, AT2 receptor, desmin, SM-22 and smooth
muscle a-actin mRNA expressions in VSMCs (P-9) in the absence ()
or presence (+) of heparin. Expressions in the heparin () group were
set at 1.0 (n = 3 each). Results are expressed as means ± S.E.M.
\P < 0.05 vs. heparin () group.
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2.2. Real-time quantitative reverse transcription-PCR
Real-time quantitative reverse transcription (RT)-PCR was per-
formed to determine AT1 receptor, AT2 receptor, desmin, SM-22
and smooth muscle a-actin expression in VSMCs as described
[14–16]. PCR was performed by incubating the RT product with the
TaqMan Universal PCR Master Mix and designed TaqMan probe
(Applied Biosystems, CA, USA). Each sample was added in triplicate.
Wells were sealed with optical sheet, and the PCR reaction was run on
an ABI prism 7700 using standard conditions. RNA quantity was ex-
pressed relative to 18S endogenous control. Relative expression levels
were expressed by comparative threshold cycle (CT) method as de-
scribed previously [15].
2.3. Immunoﬂuorescence staining
Immunoﬂuorescence staining was performed to determine smooth
muscle a-actin expression in VSMCs. VSMCs at the ninth passage
were grown in D-MEM supplemented with 1% FBS with or without
heparin for 6 days on glass slides, ﬁxed in 2% paraformaldehyde for
15 min and stained with anti-smooth muscle a-actin (1:100, Dako,
Glostrup, Denmark), followed by anti-mouse IgG coupled with FITC
(Molecular Probes, OR, USA).
2.4. Western-blot analysis
Expression of AT1 receptor protein and phosphorylated ERK or
p38 were examined by immunoblotting as previously described
[13,15,16]. VSMCs at subconﬂuence were serumdeprived for 24 h
and then stimulated as indicated. Soluble proteins (25–100 mg) were
fractionated on 10% SDS–polyacrylamide gels and transferred to
PVDF membranes (Millipore, MA, USA). Activation of ERK1/2 by
phosphorylation on threonine 202 and tyrosine 204 was revealed by
immunoblotting with mouse monoclonal antibody against the phos-
pho-ERK1/2 (1:1000, Cell Signaling, MA, USA), while total ERK1/2
protein was detected using rabbit polyclonal antibodies against
ERK1/2 (1:5000, Upstate, VA, USA). A similar procedure was used
for immunoblotting with polyclonal phospho-p38 antibody (1:1000,
Promega), total p38 antibody(1:1000, Cell Signaling), AT1 receptor
antibody (1:1000, Santa Cruz, CA, USA) or monoclonal b-actin anti-
body (1:10000, Sigma). The immunoreactive bands were visualized by
ECL plus reagent (Amersham Biosciences, NJ, USA), and the images
were analyzed by densitometry using NIH image (NIH, MD, USA).
2.5. Statistical analysis
Data are expressed as means ± S.E.M. Statistical signiﬁcance was
determined by ANOVA (StatView, SAS Institute Inc., NC, USA).Fig. 3. AT1 receptor protein expression in VSMCs (P-9) in the absence
() or presence (+) of heparin. Results are expressed as mean-
s ± S.E.M. \P < 0.05 vs. heparin () group.3. Results
3.1. Eﬀect of heparin on AT1 and AT2 receptor expression in
VSMCs
The expression of AT1 and AT2 receptor mRNA was 0.60
and 0.61 times smaller, respectively, in VSMCs cultured in
D-MEM containing 1% FBS at the ninth passage than in those
cells at the third passage (Fig. 1). On the other hand, the levels
of desmin, SM-22 and smooth muscle a-actin mRNA showed
signiﬁcant decrease already after the third passage of the cul-
ture, and did not change during the third and the ninth pas-
sages (data not shown).
In VSMCs at the ninth passage, heparin signiﬁcantly in-
creased AT1 and AT2 receptor gene expression by 2.0 and 3.0
times, respectively (Fig. 2). This increase in AT1 receptor was
observed also at the level of protein expression (Fig. 3). Heparin
did not have any eﬀect onb-actin protein expression.Under hep-
arin-containing condition, desmin, SM-22 and smooth muscle
a-actin mRNA was found to increase by 2.9, 2.3 and 1.5 times,respectively (Fig. 2). VSMCs exhibited the typical spindle-
shaped morphology with a hills-and-valleys pattern, and
displayed typical stress ﬁbers after staining with anti-smooth
muscle a-actin antibody. As shown in Fig. 4, strongly stained
cells were found in the heparin-treated cells. On the other hand,
smoothmuscle a-actin-positive cells were sparsely distributed in
the non-treated cells at the ninth passage in our experimental
condition (Fig. 4). The concentration of heparin in used here
hasmaximal inhibitory eﬀects on proliferation ofVSMCs [8,12].
Fig. 4. Immunoﬂuorescent analysis of smooth muscle a-actin expres-
sion in VSMCs (P-9) in the absence () or presence (+) of heparin.
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To investigate whether the increase of AT1 receptor expres-
sion by heparin was linking to intracellular signal transduc-
tion, VSMCs were treated with Ang II and detected
phosphorylated ERK1/2 or p38 by immunoblotting. As shown
in Fig. 5, the basal levels of phosphorylated ERK1/2 and p38
were similar in control and heparin-treated groups.
Ang II (0.1 mM) promoted a time-dependent formation of
both phosphrylated ERK1/2 and p38 proteins with maximum
levels occurring 5 min after the treatment. The mean levels of
phosphorylated ERK1/2 and p38 were 1.4 and 1.7 times,
respectively, higher in heparin-treated VSMCs than in non-
treated VSMCs only at the maximum level, the 5 min (Fig. 5).4. Discussion
The biological features of VSMCs in culture have been
extensively studied [3,4,16,17]. Mature VSMCs express unique
isoforms of a various contractile and structural proteins that
are important for their function. After the explant, these diﬀer-
entiation markers rapidly degraded. The levels of smooth mus-Fig. 5. Ang II-induced phosphorylation of ERK1/2 (A) and p38 (B) in VSM
exposed to 0.1 mM Ang II for the indicated periods of time. Immunoblottin
anti-total-ERK1/2 antibody (A, lower panel), anti-phospho-p38 antibody (B,
expressed as means ± S.E.M. \P < 0.05 vs. heparin () at the 5 min group.cle a-actin, smooth muscle myosin heavy chains, desmin and
smoothlin were reported to show signiﬁcant decrease already
after the ﬁrst passage of the culture, when VSMCs were incu-
bated with FBS-containing medium [12]. This evidence may
explain the present observation that desmin, SM-22 and
smooth muscle a-actin mRNA expression did not change dur-
ing the third and ninth passages.
The eﬀect of heparin on the phenotype is to induce the mark-
ers of mature VSMCs such as smooth muscle a-actin, smooth
muscle myosin heavy chains 2 and smoothlin [8,10,12]. The
present experiments demonstrated that heparin signiﬁcantly
increased the expression of desmin, SM-22 and smooth muscle
a-actin mRNA in VSMCs at the ninth culture passage. Be-
cause these proteins have indispensable roles for the cellular
performance of VSMCs on the vessel wall structure and func-
tions, heparin-treatment may be of value for cultured VSMCs
to be used as a highly diﬀerentiated cellular model.
As observed for the diﬀerentiation markers, AT1 receptor
expression in VSMCs decreases during culture passages [6].
The present experiments conﬁrmed that the levels of AT1 recep-
tor mRNA at the ninth passage were 0.6 times lower than those
at the third passage. The passage-dependent decrease in the lev-
els of AT2 receptor mRNA was also observed. The present
study demonstrated for the ﬁrst time that heparin recovered
AT1 and AT2 receptor expression. Considering the parallel
relationship between the expression of these receptors and dif-
ferentiation markers, it could be speculated that the eﬀect of
heparin to maintain the contractile phenotype contributes to
the increased these receptors expression in VSMCs. Further-
more, we demonstrated here that heparin potenciated Ang
II-induced phosphorylation of ERK1/2 and p38. In VSMCs,
mitogen-activated protein kinase (MAPK) including ERK1/2
and p38 is the central pathway of intracellular signal transduc-
tion of AT1 receptor, which plays a major role for VSMCs dis-
playing the physiological function as a cellular constituent of
vasculature [18]. These results indicated that heparin-treatment
may be of value for cultured VSMCs to be used to maintain the
condition of lower passage.Cs (P-9) in the absence () or presence (+) of heparin. VSMCs were
g was performed with anti-phospho-ERK antibody (A, upper panel),
upper panel) and anti-total-p38 antibody (B, lower panel). Results are
P < 0.05 vs. 0 min group.
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enriched sucrose gradient membrane fractions, which are in-
volved inAng II signaling inVSMCs [19,20]. Caveolin-mediated
intracellular signals may be involved in a possible mechanism of
the eﬀect of heparin. Heparin and its derivatives may directly
attenuate the interaction of FGF-2 and its receptor (FGFR)
by binding to FGF-2, FGFR, or to both of them [21]. FGF-2
mediates, at least partly, the stimulating eﬀect of Ang II on cell
proliferation of VSMCs [22]. At the present, however, the pre-
cise mechanism contributing to the heparin action remains to
be elucidated. Further studies will be needed to determine the
intracellular signaling pathways in response to heparin.
In summary, the expression of AT1 and AT2 receptor was
decreased during culture passage in VSMCs. Heparin recov-
ered these receptors as well as the other diﬀerentiation markers
of the cells. Heparin also potenciated Ang II-induced phos-
phorylation of ERK1/2 and p38 in VSMCs. These evidences
indicated the potential value of heparin-treatment in the anal-
ysis of AT1 receptor signal transduction in VSMCs under the
physiological condition.
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